3,047 Shares in Danaher Corporation $DHR Purchased by TritonPoint Partners LLC

TritonPoint Partners LLC purchased a new position in shares of Danaher Corporation (NYSE:DHR) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 3,047 shares of the conglomerate’s stock, valued at approximately $699,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. State Street Corp boosted its holdings in Danaher by 1.7% in the 4th quarter. State Street Corp now owns 27,681,334 shares of the conglomerate’s stock valued at $6,345,529,000 after purchasing an additional 472,608 shares during the last quarter. Capital International Investors boosted its holdings in Danaher by 8.9% in the 4th quarter. Capital International Investors now owns 18,246,008 shares of the conglomerate’s stock valued at $4,177,386,000 after purchasing an additional 1,487,768 shares during the last quarter. Norges Bank acquired a new position in Danaher in the 4th quarter valued at about $2,177,106,000. Generation Investment Management LLP boosted its holdings in Danaher by 14.1% in the 4th quarter. Generation Investment Management LLP now owns 7,589,661 shares of the conglomerate’s stock valued at $1,737,425,000 after purchasing an additional 934,995 shares during the last quarter. Finally, Franklin Resources Inc. boosted its holdings in Danaher by 14.9% in the 4th quarter. Franklin Resources Inc. now owns 4,931,303 shares of the conglomerate’s stock valued at $1,128,874,000 after purchasing an additional 637,666 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher closed its $9.9 billion acquisition of Masimo, expanding its diagnostics and patient-monitoring portfolio with AI-enabled sensor technologies that could support longer-term growth. Danaher Boosts Product Portfolio With the Acquisition of Masimo
• Positive Sentiment: Cepheid, a Danaher company, donated Xpert Hemorrhagic Fever panel tests to support Ebola outbreak response in Africa, highlighting the company’s diagnostic relevance and public-health role. Cepheid Delivers Xpert Hemorrhagic Fever Panel Tests to Africa
• Positive Sentiment: Analysts noted strong performance in Danaher’s biotechnology unit, with bioprocessing demand and equipment orders rising, which supports the company’s 2026 growth outlook. Strong Performance Continues at DHR’s Biotechnology Unit: What’s Next?

Danaher Stock Performance

Shares of DHR stock opened at $179.95 on Monday. The firm’s 50 day moving average price is $180.93 and its 200-day moving average price is $204.62. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.52 and a current ratio of 1.87. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80. The firm has a market cap of $127.37 billion, a P/E ratio of 34.81, a P/E/G ratio of 2.30 and a beta of 0.81.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Monday, April 20th. The conglomerate reported $2.06 EPS for the quarter, topping the consensus estimate of $1.94 by $0.12. Danaher had a net margin of 14.89% and a return on equity of 10.91%. The firm had revenue of $5.95 billion for the quarter, compared to analyst estimates of $6 billion. During the same period in the prior year, the business posted $1.88 EPS. The business’s revenue for the quarter was up 3.7% compared to the same quarter last year. As a group, equities research analysts predict that Danaher Corporation will post 8.45 EPS for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be issued a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Friday, June 26th. Danaher’s dividend payout ratio is currently 30.95%.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on DHR shares. UBS Group decreased their target price on shares of Danaher from $270.00 to $250.00 and set a “buy” rating on the stock in a report on Wednesday, April 22nd. Barclays decreased their target price on shares of Danaher from $250.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday, April 14th. Evercore boosted their target price on shares of Danaher from $225.00 to $232.00 and gave the company an “outperform” rating in a report on Tuesday, April 21st. Guggenheim decreased their target price on shares of Danaher from $275.00 to $235.00 and set a “buy” rating on the stock in a report on Wednesday, April 22nd. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Danaher in a report on Friday, March 27th. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $233.61.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.